Immunotherapy in EGFR-mutant NSCLC after TKI resistance: role of mutation subtypes and progression patterns

Abstract excerpt

BACKGROUND: Patients withEGFR-sensitizing mutations in non-small cell lung cancer (NSCLC) predominantly receive first-line tyrosine kinase inhibitors (TKIs). Subsequent TKI resistance manifests through heterogeneous clinicopathological features, including distinct resistance subtypes (primary vs. acquired),PD-L1expression levels, and molecular profiles from re-biopsies. While immunotherapy represents a potential...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Immunotherapy and Biomarkers
• Share to Lung Cancer Diagnosis and Treatment
• Share to Lung Cancer Treatments and Mutations